1. How many patients has your trust treated in the last 12 months with the following drugs?
a. Genotropin
b. Humatrope
c. Norditropin
d. Nutropin
e. Omnitrope
f. Saizen
g. Zomacton
h. Any other Somatropin (please specify)
2. Please provide the number of patients under the age of 16 that were treated in the last 12 months with each of the following drugs:
a. Genotropin
b. Humatrope
c. Norditropin
d. Nutropin
e. Omnitrope
f. Saizen
g. Zomacton
h. Any other Somatropin (please specify)
3. Within your trust, how many patients have been diagnosed (primary or secondary diagnosis) in the past 12 months for the following conditions:
a. Neuromuscular dysfunction of bladder (ICD-10 Code N31.9)
b. Cervical dystonia (ICD-10 code G24.3)
4. For patients diagnosed with neuromuscular dysfunction of bladder as per question 3 above, how many patients have been treated in the last 3 months with the following products:
a. Botox
b. Dysport
c. Xeomin
5. For patients diagnosed with cervical dystonia as per question c above, how many patients have been treated in the last 3 months with the following products:
a. Botox
b. Dysport
c. Xeomin

Download response Growth Hormone and Spasticity. 310821.docx